CN1559463A - Medicine for treating viral hepatitis B - Google Patents
Medicine for treating viral hepatitis B Download PDFInfo
- Publication number
- CN1559463A CN1559463A CNA2004100057148A CN200410005714A CN1559463A CN 1559463 A CN1559463 A CN 1559463A CN A2004100057148 A CNA2004100057148 A CN A2004100057148A CN 200410005714 A CN200410005714 A CN 200410005714A CN 1559463 A CN1559463 A CN 1559463A
- Authority
- CN
- China
- Prior art keywords
- herba
- mass fraction
- shared mass
- viral hepatitis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of decoction or instant particles for treating viral hepatitis B is prepared from 12 Chinese-medicinal materials including prunella spike, capejasmine fruit, oldenlandia, plantain herb, etc.
Description
Technical field: the present invention relates to a kind of medicine for the treatment of hepatitis B, particularly a kind of technical field that becomes the medicine of treatment Type B viral hepatitis with prepared from traditional Chinese medicines.
Background technology: hepatitis, particularly Type B viral hepatitis are a kind of difficult healings and infect the infectious disease of giving other people especially easily that at present, no matter the traditional Chinese medical science still is doctor trained in Western medicine is not all had specific drug to this.In many medicines of present stage treatment hepatitis B, use more a kind of interferon, even use interferon, still be difficult to eliminate the carrier state of hepatitis B surface antigen (HBsAg), cause some Type B viral hepatitis patients to develop into liver cirrhosis even hepatocarcinoma, cause very big injury for patient and family thereof.
Summary of the invention: technical problem to be solved by this invention provides a kind of negative conversion rate that can overcome above-mentioned defective, hepatitis B surface antigen and reaches more than 90%, improves symptom, sign and liver function, has the hepatitis B virus of killing, promotes liver cell regeneration, strengthens liver immunity, reduce chronic type B viral hepatitis and transform, finally make the medicine of the restorative treatment Type B viral hepatitis of patient to liver cirrhosis even hepatocarcinoma.The technical scheme that solves this technical problem employing is: a kind of medicine for the treatment of Type B viral hepatitis, it is characterized in that it is by Herba Verbenae, Caulis et folium pavettae hongkongensis, Spica Prunellae, Herba Lycopodii, Herba Melicae Scabrosae, Herba Centellae, Herba Hyperici Japonici, Elephantopus scaber L., Fructus Gardeniae, Herba Kalimeridis, Herba Hedyotidis Diffusae, Herba Plantaginis, the medicament of making by the raw material of following mass fraction combination, wherein the shared mass fraction of Herba Verbenae is 1-5, the shared mass fraction of Caulis et folium pavettae hongkongensis is 3-9, the shared mass fraction of Spica Prunellae is 1-5, the shared mass fraction of Herba Lycopodii is 5-13, the shared mass fraction of Herba Melicae Scabrosae is 1-5, the shared mass fraction of Herba Centellae is 3-9, the shared mass fraction of Herba Hyperici Japonici is 5-13, the shared mass fraction of Elephantopus scaber L. is 1-5, the shared mass fraction of Fructus Gardeniae is 7-17, the shared mass fraction of Herba Kalimeridis is 4-11, the shared mass fraction of Herba Hedyotidis Diffusae is 6-15, the shared mass fraction of Herba Plantaginis is 1-5, and this drug agents is said arbitrary dosage form on the pharmaceutics.When the mass fraction of Herba Verbenae, Caulis et folium pavettae hongkongensis, Spica Prunellae, Herba Lycopodii, Herba Melicae Scabrosae, Herba Centellae, Herba Hyperici Japonici, Elephantopus scaber L., Fructus Gardeniae, Herba Kalimeridis, Herba Hedyotidis Diffusae, Herba Plantaginis was respectively 2,4,2,6,2,4,6,2,8,5,7,2, made decoction was mainly used in the Type B viral hepatitis patient of treatment small three positive; When the mass fraction of Herba Verbenae, Caulis et folium pavettae hongkongensis, Spica Prunellae, Herba Lycopodii, Herba Melicae Scabrosae, Herba Centellae, Herba Hyperici Japonici, Elephantopus scaber L., Fructus Gardeniae, Herba Kalimeridis, Herba Hedyotidis Diffusae, Herba Plantaginis was respectively 4,8,4,12,4,8,12,4,16,10,14,4, made decoction was mainly used in the Type B viral hepatitis patient of treatment great three positive.The present invention compared with prior art has following beneficial effect: 1. the present invention constitutes simply, and raw materials for production are easy to get, and all adopts natural Chinese medicinal herb; 2. production method of the present invention is simple, and cost is low; 3. patient's taking convenience, safe and reliable, short treating period, effect is remarkable, and clinical practice shows that the negative conversion rate of patient's hepatitis B surface antigen (HBsAg) reaches more than 90%.4. the present invention also has good therapeutic effect to the viral hepatitis of other type.
The specific embodiment: embodiment 1 is the medicine of treatment Type B viral hepatitis (small three positive), with Herba Verbenae, Caulis et folium pavettae hongkongensis, Spica Prunellae, Herba Lycopodii, Herba Melicae Scabrosae, Herba Centellae, Herba Hyperici Japonici, Elephantopus scaber L., Fructus Gardeniae, Herba Kalimeridis, Herba Hedyotidis Diffusae, the dried Chinese herbal medicine of Herba Plantaginis, with the gram is that unit gets 2 respectively, 4,2,6,2,4,6,2,8,5,7,2 grams, add water 800 to 900 grams, decocting adds white sugar 20 grams after boiling into decoction, use for three taking medicine before meal of patient's one bu, through one, two courses of treatment, be can reach a therapeutic effect in month each course of treatment, and promptly hepatitis B surface antigen (HBsAg) negative conversion rate reaches more than 90%.Embodiment 2 is the medicine of treatment Type B viral hepatitis (great three positive), with Herba Verbenae, Caulis et folium pavettae hongkongensis, Spica Prunellae, Herba Lycopodii, Herba Melicae Scabrosae, Herba Centellae, Herba Hyperici Japonici, Elephantopus scaber L., Fructus Gardeniae, Herba Kalimeridis, Herba Hedyotidis Diffusae, the dried Chinese herbal medicine of Herba Plantaginis, with the gram is that unit gets 4 respectively, 8,4,12,4,8,12,4,16,10,14,4 grams, add water 800 to 900 grams, decocting adds white sugar 20 grams after boiling into decoction, use for three taking medicine before meal of patient's one bu, through one, two, three courses of treatment, be one month each course of treatment, can reach therapeutic effect, promptly hepatitis B surface antigen (HBsAg) negative conversion rate reaches more than 90%.Show that through clinical practice the present invention constitutes simply, raw material is easy to get, and all adopts natural Chinese medicinal herb, and production method is simple, and cost is low, patient's taking convenience, safe and reliable, short treating period, effect is remarkable, and the negative conversion rate of patient's hepatitis B surface antigen (HBsAg) reaches more than 90%.
Description of drawings: Fig. 1 is that figure is xeroxed in the whole strain of the grass medicine of " Caulis et folium pavettae hongkongensis " of the present invention.
Claims (4)
1, a kind of medicine for the treatment of Type B viral hepatitis, it is characterized in that it is by Herba Verbenae, Caulis et folium pavettae hongkongensis, Spica Prunellae, Herba Lycopodii, Herba Melicae Scabrosae, Herba Centellae, Herba Hyperici Japonici, Elephantopus scaber L., Fructus Gardeniae, Herba Kalimeridis, Herba Hedyotidis Diffusae, the medicament that Herba Plantaginis is made by the raw material of following mass fraction combination, wherein the shared mass fraction of Herba Verbenae is 1-5, the shared mass fraction of Caulis et folium pavettae hongkongensis is 3-9, the shared mass fraction of Spica Prunellae is 1-5, the shared mass fraction of Herba Lycopodii is 5-13, the shared mass fraction of Herba Melicae Scabrosae is 1-5, the shared mass fraction of Herba Centellae is 3-9, the shared mass fraction of Herba Hyperici Japonici is 5-13, the shared mass fraction of Elephantopus scaber L. is 1-5, the shared mass fraction of Fructus Gardeniae is 7-17, the shared mass fraction of Herba Kalimeridis is 4-11, the shared mass fraction of Herba Hedyotidis Diffusae is 6-15, the shared mass fraction of Herba Plantaginis is 1-5.
2, a kind of medicine for the treatment of Type B viral hepatitis according to claim 1, it is characterized in that wherein that when the mass fraction of Herba Verbenae, Caulis et folium pavettae hongkongensis, Spica Prunellae, Herba Lycopodii, Herba Melicae Scabrosae, Herba Centellae, Herba Hyperici Japonici, Elephantopus scaber L., Fructus Gardeniae, Herba Kalimeridis, Herba Hedyotidis Diffusae, Herba Plantaginis is respectively 2,4,2,6,2,4,6,2,8,5,7,2 made decoction is mainly used in the Type B viral hepatitis patient of treatment small three positive.
3, a kind of medicine for the treatment of Type B viral hepatitis according to claim 1, it is characterized in that wherein that when the mass fraction of Herba Verbenae, Caulis et folium pavettae hongkongensis, Spica Prunellae, Herba Lycopodii, Herba Melicae Scabrosae, Herba Centellae, Herba Hyperici Japonici, Elephantopus scaber L., Fructus Gardeniae, Herba Kalimeridis, Herba Hedyotidis Diffusae, Herba Plantaginis is respectively 4,8,4,12,4,8,12,4,16,10,14,4 made decoction is mainly used in the Type B viral hepatitis patient of treatment great three positive.
4, a kind of medicine for the treatment of Type B viral hepatitis according to claim 1 is characterized in that described medicament is said arbitrary dosage form on the pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410005714 CN1234400C (en) | 2004-02-18 | 2004-02-18 | Medicine for treating viral hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410005714 CN1234400C (en) | 2004-02-18 | 2004-02-18 | Medicine for treating viral hepatitis B |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1559463A true CN1559463A (en) | 2005-01-05 |
| CN1234400C CN1234400C (en) | 2006-01-04 |
Family
ID=34439670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410005714 Expired - Fee Related CN1234400C (en) | 2004-02-18 | 2004-02-18 | Medicine for treating viral hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1234400C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784366A (en) * | 2012-09-03 | 2012-11-21 | 赵全成 | Medical composition with function of decanting and protecting liver |
| WO2023241179A1 (en) * | 2022-06-17 | 2023-12-21 | 重庆医科大学检验医学院 | Use of asiatic acid in preparation of medicament for treating hepatitis b |
-
2004
- 2004-02-18 CN CN 200410005714 patent/CN1234400C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102784366A (en) * | 2012-09-03 | 2012-11-21 | 赵全成 | Medical composition with function of decanting and protecting liver |
| CN102784366B (en) * | 2012-09-03 | 2013-07-31 | 赵全成 | Medical composition with function of decanting and protecting liver |
| WO2023241179A1 (en) * | 2022-06-17 | 2023-12-21 | 重庆医科大学检验医学院 | Use of asiatic acid in preparation of medicament for treating hepatitis b |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1234400C (en) | 2006-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1076120A (en) | Medical liquid for relaxing tendons and joints | |
| CN1224614A (en) | Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation | |
| CN1824205B (en) | Medicine for treating chronic prostatitis and its preparation method | |
| CN101134085A (en) | Traditional Chinese medicine for treating apoplexy and hemiplegia | |
| CN101361946B (en) | Traditional Chinese medicine combination for treating hepatitis B | |
| CN1047090C (en) | Plaster for curing cough with dyspnea | |
| CN1145240A (en) | Medicinal compsn. for prevention of Aids virus and cancer | |
| CN1270765C (en) | Medicinal wine or liquid for treating cold | |
| CN101732403A (en) | Chinese medicament for treating muguet | |
| CN101167932A (en) | Traditional Chinese medicine for treating chronic hepatitis B | |
| CN101130053A (en) | Traditional Chinese medicine for treating exogenous injury type blood stasis headache | |
| CN1234400C (en) | Medicine for treating viral hepatitis B | |
| CN1100642A (en) | Traditional Chinese medicine prepn. for curing B-hepatitis | |
| CN1283497A (en) | Oral liquid for treating cerebrovascular disease and its preparing process | |
| CN1060368C (en) | Traditional Chinese medicine Jinjiangkebao for treating cough | |
| CN1356124A (en) | Medicine for treating hepatism | |
| CN101167969A (en) | Traditional Chinese medicine for treating meniere's syndrome | |
| CN1090183A (en) | Artemisia scoparia and ginseng pellet for mourishing liver and method for production thereof | |
| CN103705829B (en) | A kind of medicine for the treatment of hepatopathy | |
| CN102743658A (en) | Traditional Chinese medicinal composition for treating urticaria | |
| CN1235840A (en) | Chinese medicine powder for curing rheumatoid and rheumatic diseases | |
| CN1091026A (en) | Danshixiao medicine for treating cholelithiasis | |
| CN1403140A (en) | Medicine for treating acute and chronic hepatitis B | |
| CN1404847A (en) | Medicine for treating sequel resulted from cardio-cerebral blood-vessel diseases | |
| CN1137697C (en) | Compound medicinal powder for treating tuberculosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060104 |